This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Orexigen Therapeutics' CEO Presents At Morgan Stanley Healthcare Conference (Transcript)

Orexigen Therapeutics (OREX)

Presentation at Morgan Stanley Healthcare Conference

September 12, 2012 10:55 a.m. ET


Michael Narachi - President and CEO


Marshall Urist - Morgan Stanley


Marshall Urist - Morgan Stanley

Hello everyone, I’m Marshall Urist, one of the biotech analysts here at Morgan Stanley. Two quick pieces of business. Number one, all of our research disclosures can be found on our printed research or our website. And number two is this is absolutely supposed to be an interactive session, so any questions once we jump into the Q&A, please just raise your hand and there are microphones circulating.

So with that, we are excited to sit down with Mike Narachi, president and CEO of Orexigen. Mike, thanks for joining us today. Maybe the best way to start is just take a couple of minutes to talk about the strategic focus right now, what you guys are focused on, before we jump into some specifics.

Michael Narachi

Thanks, and thanks for coming, and for your interest today. First, I guess I should always say that I will be making forward looking statements, things materially change in the future from time to time in our industry, as you know. And all of our disclosures are on our website and in our SEC filings.

The obesity space in general for you, let’s just first start taking a step back, is one of our many and probably an underlying chronic disease issue that’s facing pretty much the entire developed world and developing world. And it’s a difficult problem to attack, because it’s fundamental to lots of biology and it’s a societal issue. It’s a biologic issue, it’s a personal medical issue.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs